Brian McGuinness
Corporate Officer/Principal chez Crescendo Biologics Ltd.
Profil
Brian McGuinness is currently the Head of New Product and Business Opportunities at Crescendo Biologics Ltd.
He previously worked as an Evaluation Manager in Business Development at MedImmune Ltd.
and as an Associate Consultant at Apex Healthcare, Inc. He also held positions as a Principal at IP2IPO Innovations Ltd., AstraZeneca UK Ltd., BerGenBio ASA, and as a Technology Consultant at Heptares Therapeutics Ltd.
Additionally, he worked as a Consultant at Algeta ASA and as an Associate Consultant at Alacrita LLP.
Dr. McGuinness holds a doctorate degree from The University of Southampton, an undergraduate degree from the University of Bristol, and an MBA from The Open University.
Postes actifs de Brian McGuinness
| Sociétés | Poste | Début |
|---|---|---|
Crescendo Biologics Ltd.
 Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Anciens postes connus de Brian McGuinness
| Sociétés | Poste | Fin |
|---|---|---|
IP2IPO Innovations Ltd.
 IP2IPO Innovations Ltd. Miscellaneous Commercial ServicesCommercial Services IP2IPO Innovations Ltd. provides business development and technology transfer services. The firm also provides strategic industry University partnerships, patenting, licensing, spin-out incubation and equity management services. The company was founded in 1986 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Apex Healthcare, Inc.
 Apex Healthcare, Inc. Internet Software/ServicesTechnology Services Apex Healthcare, Inc. provides web based managed care technology and administrative service solutions. Its services include on-line eligibility, claims and utilization review data, information management, and enrollment and eligibility administration. The company was founded in 1996 and is headquartered in Bolingbrook, IL. | Corporate Officer/Principal | - |
| BERGENBIO ASA | Corporate Officer/Principal | - |
Alacrita LLP
 Alacrita LLP Miscellaneous Commercial ServicesCommercial Services Alacrita LLP is an expertise-based consulting firm that offers consulting support on a range of R&D and business issues to biotech and pharma companies, academic institutions, and healthcare investors. Alacrita was founded in 2009 by Anthony Ian Walker and is based in London, UK. The British company conducts more than 250 successful client assignments every year and has a broad network of specialized consultants who can be engaged as necessary when additional, specialized expertise is required. Its core team leverages a consulting network of 250+ functional specialists, all with at least 20 years of pharmaceutical industry experience, allowing it to offer a versatile combination of depth and breadth in expertise that is unrivaled in the industry and that can be precisely tailored to the needs of each client. | Corporate Officer/Principal | - |
| ALGETA ASA | Corporate Officer/Principal | - |
Formation de Brian McGuinness
| The University of Southampton | Doctorate Degree |
| University of Bristol | Undergraduate Degree |
| The Open University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BERGENBIO ASA | Health Technology |
| Entreprise privées | 8 |
|---|---|
MedImmune Ltd.
 MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Apex Healthcare, Inc.
Apex Healthcare, Inc. Internet Software/ServicesTechnology Services Apex Healthcare, Inc. provides web based managed care technology and administrative service solutions. Its services include on-line eligibility, claims and utilization review data, information management, and enrollment and eligibility administration. The company was founded in 1996 and is headquartered in Bolingbrook, IL. | Technology Services |
IP2IPO Innovations Ltd.
IP2IPO Innovations Ltd. Miscellaneous Commercial ServicesCommercial Services IP2IPO Innovations Ltd. provides business development and technology transfer services. The firm also provides strategic industry University partnerships, patenting, licensing, spin-out incubation and equity management services. The company was founded in 1986 and is headquartered in London, the United Kingdom. | Commercial Services |
AstraZeneca UK Ltd.
 AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. | Commercial Services |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Health Technology |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Alacrita LLP
Alacrita LLP Miscellaneous Commercial ServicesCommercial Services Alacrita LLP is an expertise-based consulting firm that offers consulting support on a range of R&D and business issues to biotech and pharma companies, academic institutions, and healthcare investors. Alacrita was founded in 2009 by Anthony Ian Walker and is based in London, UK. The British company conducts more than 250 successful client assignments every year and has a broad network of specialized consultants who can be engaged as necessary when additional, specialized expertise is required. Its core team leverages a consulting network of 250+ functional specialists, all with at least 20 years of pharmaceutical industry experience, allowing it to offer a versatile combination of depth and breadth in expertise that is unrivaled in the industry and that can be precisely tailored to the needs of each client. | Commercial Services |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
